Content area
Full Text
http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = J Gastroenterol (2015) 50:758768 DOI 10.1007/s00535-014-1020-5
http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = ORIGINAL ARTICLEALIMENTARY TRACT
http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00535-014-1020-5&domain=pdf
Web End = Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotypein patients with Crohns disease
Oriol Juanola Alba Moratalla Ana Gutirrez Laura Sempere
Pedro Zapater Paula Gimnez Isabel Almenta Gloria Peir
Jos M. Gonzlez-Navajas Jos F. Such Rubn Francs
Received: 11 August 2014 / Accepted: 20 November 2014 / Published online: 11 December 2014 Springer Japan 2014
AbstractBackground Anti-TNF-a therapies interact with the tolerogenic response in patients with Crohns disease, modulating inammation. However, drug levels and the genetic background may affect this interaction.
Methods Patients with Crohns disease in remission on biologic monotherapy were enrolled in this study. FoxP3? lymphocytes, NOD2 genotype, serum cytokine, anti-TNF-a levels, and anti-drug antibodies were evaluated. Regulatory T cell response to iniximab was evaluated in vitro.
Electronic supplementary material The online version of this article (doi:http://dx.doi.org/10.1007/s00535-014-1020-5
Web End =10.1007/s00535-014-1020-5 ) contains supplementary material, which is available to authorized users.
O. Juanola A. Moratalla P. Zapater P. Gimnez
J. M. Gonzlez-Navajas J. F. Such R. Francs
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
O. Juanola A. Moratalla A. Gutirrez L. Sempere
P. Gimnez I. Almenta J. M. Gonzlez-Navajas
R. Francs (&)
Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Avda. Pintor Baeza 12, 03010 Alicante, Spain e-mail: [email protected]
P. ZapaterServicio de Farmacologa Clnica, Hospital General Universitario de Alicante, Alicante, Spain
G. PeirServicio de Anatoma Patolgica, Hospital General Universitario de Alicante, Alicante, Spain
J. F. SuchDigestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
R. FrancsDpto. Medicina Clnica, Universidad Miguel Hernndez, San Juan De Alicante, Spain
Results Fifty-seven patients were included. Thirty-nine patients (68.4 %) were receiving non-intensied biologic therapy whereas 18 patients (31.6 %) were under an intensied biologic schedule due to loss of response. Eleven intensied patients (61.1 %) showed a variant NOD2 genotype vs 9 on non-intensied biologics (23 %, p \ 0.01). Percentage of FoxP3? T cells and serum free anti-TNF-a levels were signicantly higher in patients with...